On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
REGULATORY
Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
Japan’s key reimbursement policy panel on October 23 gave a cold shoulder to the pharma industry’s call for giving more flexibility to the selection of comparator products in new drug pricing - a proposal towards the next pricing reform in…
To read the full story
Related Article
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- Revisit Comparator Selection Criteria for New Drug Pricing: JPMA
June 28, 2019
REGULATORY
- Fujimoto’s Thaled Now in Line for Approval for POEMS Syndrome
January 28, 2021
- MHLW Official Urges Pref. Govts to Implement Thorough Inspection, Guidance for Drug Makers after Kobayashi Kako Fiasco
January 28, 2021
- LDP COVID-19 Vaccine Project Team to Compile Proposal before Rollout
January 27, 2021
- Label Revisions Ordered for Pomalyst, MabCampath, and More
January 27, 2021
- Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…